Skip to main content
Journal cover image

Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.

Publication ,  Journal Article
Patel, K; Lajoie, A; Heaton, S; Pianko, S; Behling, CA; Bylund, D; Pockros, PJ; Blatt, LM; Conrad, A; McHutchison, JG
Published in: J Gastroenterol Hepatol
March 2003

BACKGROUND AND AIM: Hyaluronic acid (HA) is a glycosaminoglycan synthesized by hepatic stellate cells that has been shown to correlate with liver fibrosis in chronic hepatitis C (HCV) patients. However, its use in monitoring fibrosis over time has not been established. The aim of the present study was to assess the serial relationships between HA and liver fibrosis before and after treatment. METHODS: Seventy-six previously untreated chronic HCV patients received interferon-based therapy over 48 weeks. Serum HA levels were measured and liver biopsies were obtained at baseline, and 24 weeks post-treatment. Histological fibrosis was assessed by using the Knodell and METAVIR scoring systems. RESULTS: Knodell fibrosis was evaluated in 76 patients; METAVIR fibrosis in 72 patients. Following treatment, patients were grouped into those with increased fibrosis (Knodell = 17; METAVIR = 16), no change (Knodell = 50; METAVIR = 45), or decreased fibrosis (Knodell = 9; METAVIR = 11), relative to baseline. Moderate correlations between HA and fibrosis scores were found before treatment (Knodell R = 0.45; METAVIR R = 0.40) and post-treatment (Knodell R = 0.45; METAVIR R = 0.61). However, changes in HA correlated poorly with changes in fibrosis scores over the study period (Knodell R = 0.11; METAVIR R = 0.06). There was poor qualitative agreement between the direction of HA change and the direction of change in fibrosis scores (Knodell kappa = 0.04; METAVIR kappa = 0.08). The sustained virological response group (n = 18) had a significantly decreased mean HA compared with non-responders (-27.9 vs 21.7 micro g/L; P = 0.009), but pretreatment HA did not predict a response. CONCLUSIONS: Serum HA showed a modest association with hepatic fibrosis, and remains a useful non-invasive marker. However, serum HA alone has limited value in predicting histological changes over a treatment period.

Duke Scholars

Published In

J Gastroenterol Hepatol

DOI

ISSN

0815-9319

Publication Date

March 2003

Volume

18

Issue

3

Start / End Page

253 / 257

Location

Australia

Related Subject Headings

  • Time Factors
  • Statistics as Topic
  • Severity of Illness Index
  • Risk Factors
  • RNA, Viral
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Liver
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, K., Lajoie, A., Heaton, S., Pianko, S., Behling, C. A., Bylund, D., … McHutchison, J. G. (2003). Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol, 18(3), 253–257. https://doi.org/10.1046/j.1440-1746.2003.02930.x
Patel, Keyur, Adrianne Lajoie, Shanon Heaton, Stephen Pianko, Cynthia A. Behling, David Bylund, Paul J. Pockros, Lawrence M. Blatt, Andrew Conrad, and John G. McHutchison. “Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.J Gastroenterol Hepatol 18, no. 3 (March 2003): 253–57. https://doi.org/10.1046/j.1440-1746.2003.02930.x.
Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol. 2003 Mar;18(3):253–7.
Patel, Keyur, et al. “Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.J Gastroenterol Hepatol, vol. 18, no. 3, Mar. 2003, pp. 253–57. Pubmed, doi:10.1046/j.1440-1746.2003.02930.x.
Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, Pockros PJ, Blatt LM, Conrad A, McHutchison JG. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol. 2003 Mar;18(3):253–257.
Journal cover image

Published In

J Gastroenterol Hepatol

DOI

ISSN

0815-9319

Publication Date

March 2003

Volume

18

Issue

3

Start / End Page

253 / 257

Location

Australia

Related Subject Headings

  • Time Factors
  • Statistics as Topic
  • Severity of Illness Index
  • Risk Factors
  • RNA, Viral
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Liver